Dilon Acquires RMD Navigator Gamma Probes
NEWPORT NEWS, Va., Jan. 6, 2014
NEWPORT NEWS, Va., Jan. 6, 2014 /PRNewswire/ --Dilon Technologies Inc.
announced today that they acquired the assets of the Navigator gamma probe
business from RMD Instruments Corp., a subsidiary of Dynasil Corporation of
(Logo: http://photos.prnewswire.com/prnh/20140106/PH40697LOGO )
RMD Instruments has over thirty years experience in the manufacturing and
marketing of a quality range of intra operative surgical probes which are
distributed both in the US and internationally and which bring clinically
effective solutions to medical professionals. The acquired products are used
in surgery for procedures such as Sentinel Lymph Node Biopsy and Pulmonary
Wedge Resection. The company recently introduced its "Navigator 2.0™" wireless
probe which has been very well received by the market place.
"In addition to our market leadership in the small field of view molecular
breast imaging market, this acquisition is consistent with our objective of
expanding our product offering in both the diagnostic and surgical segments of
the market and comes on the heels of our recent agreement with Digirad,"
commented Robert G. Moussa, Dilon's CEO.
"We are pleased to have found a wonderful home for our Navigator Probe
technology, one of the most widely used Gamma probes for cancer surgery in the
marketplace. Dilon Technologies is well situated to expand the gamma probe
market and we look forward to working with them over the coming months to
transition the product from our manufacturing facility to Dilon," commented
Peter Sulick, Dynasil's Chairman and Interim CEO.
For the time being, Dynasil will continue to manufacture and distribute the
products, ensuring continuity in supply and regulatory compliance.
Dilon Technologies Inc. is bringing innovative new medical imagingproducts to
market. Dilon's cornerstone product, the Dilon Molecular Imaging System, is a
high-resolution, small field-of-view digital gamma camera, optimized for
MBI/BSGI. MBI utilizes radiotracer uptake to detect the increasedmetabolic
activity of breast lesions and therefore, is not affected by breast density.
Both the Dilon 6800^® and Acella^® systems provide high photon sensitivity;
and Dilon's GammaLoc^® System is the onlylocalization device on the market to
enable molecular-guided breast biopsy. Many leading medical centers around the
country are now offering MBI to their patients, including: Beth Israel and
CornellUniversity Medical Centers in New York; Kaiser Permanente of
Sacramento, CA, and The George Washington University, Washington D.C. For more
information, please visit www.dilon.com.
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures
detection and analysis technology, precision instruments and optical
components for the homeland security, medical and industrial markets including
medical imaging and sensors for non-destructive testing. Dynasil has an
impressive and growing portfolio of issued and pending U.S. patents. The
Company is based in Watertown, Massachusetts, with additional operations in
MA, MN, NY, NJ and the United Kingdom. More information about the Company is
available at www.dynasil.com.
Digirad Corporation is one of the largest national providers of in-office
nuclear cardiology imaging and ultrasoundservices to physician practices,
hospitals and imaging centers, and also sells medical diagnostic imaging
systems for nuclear cardiology and general nuclear medicine applications. For
more information, pleasevisit www.digirad.com. Dilon is the exclusive
international distributor (most countries outside the U.S.) of Digirad's lines
of molecular imaging cameras.Digirad^® and Cardius^® are registered trademarks
of Digirad Corporation.
Media Contact: Pjerin Luli
Dilon Technologies, Inc.
1 (757) 269-4910 x321
SOURCE Dilon Technologies Inc.
Press spacebar to pause and continue. Press esc to stop.